Oct. 31, 2011
/PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today further development progress of its second generation rPA anthrax vaccine, SparVax™. The new vaccine is being developed to provide rapid manufacturing scale-up to respond to a national security emergency. The Company completed its first cGMP manufacturing run at 1,500 liter commercial scale. Final analytical testing is ongoing and expected to be completed in December.
"There is widespread acknowledgement of the need for a modern, next-generation anthrax vaccine that can meet the government's needs in the event of an emergency. A recombinant anthrax vaccine offers the potential for an improved vaccine that is safe, convenient, cost-effective and provides for a significant increase in production yields," remarked
Eric I. Richman
, President and Chief Executive Officer. "SparVax™ is the first medical countermeasure to successfully transition from early research funded by the National Institutes of Health (NIH) to advanced development in partnership with the Biomedical Advanced Research and Development Authority (BARDA). SparVax™ represents how our medical countermeasure development program can create products with desired characteristics to meet the needs of our country. We look forward to continuing a very productive collaboration with our partners in government to address this need and advance this important product."
"This achievement marks the latest in a series of accomplishments for our rPA anthrax vaccine program in 2011," commented Dr.
, Executive Vice President and Chief Scientific Officer. "Earlier this year, we successfully completed the technology transfer of our manufacturing process from the
-based contract manufacturing organization. Most importantly, PharmAthene has data supporting 36 months of stability for SparVax™ – an important accomplishment given the historical issues associated with rPA anthrax vaccine stability. The use of recombinant vaccine technology employing modern, industrial biotechnology manufacturing processes provides the flexibility to produce a well-characterized product that can be rapidly scaled-up for production in the event of a national emergency.
A key differentiator for PharmAthene's rPA technology platform is the utilization of
. This technology enables a more robust manufacturing process and the capability of annually producing more than 150 million rPA vaccine equivalent doses of bulk drug substance (at a 50 mcg dose) – a substantial improvement in rPA production yield without the production of destructive proteases. In addition, PharmAthene's manufacturing platform has the ability to produce stable production intermediates in the event surge capacity is required. All these factors contribute to key advantages of SparVax™ over other rPA-based anthrax vaccine programs."
PharmAthene's rPA anthrax vaccine program has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Disease, National Institutes of Health and the Biomedical Advanced Research and Development Authority.